The feline vaccines market size has grown strongly in recent years. It will grow from $1.77 billion in 2025 to $1.91 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to growing pet adoption rates, increasing awareness of feline health, rising prevalence of infectious diseases, expanding veterinary care infrastructure, and growing routine vaccination compliance.
The feline vaccines market size is expected to see strong growth in the next few years. It will grow to $2.53 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to increasing demand for advanced feline immunization, growing focus on preventive veterinary healthcare, rising adoption of combination vaccines, expanding investment in companion animal biotechnology, and increasing emphasis on early-life vaccination. Major trends in the forecast period include technology-driven vaccine innovations, advancements in recombinant and dna vaccine platforms, developments in adjuvant and antigen delivery systems, rising research and development in feline immunology, and innovation in needle-free and intranasal vaccination methods.
The rising pet cat population is expected to drive the growth of the feline vaccines market in the coming years. Pet cat population refers to the increasing number of domesticated cats kept by households for companionship, emotional support, and recreational purposes. This growth is driven by higher pet adoption rates and the growing recognition of the mental and emotional benefits of pet ownership. Feline vaccines help lower the prevalence of infectious diseases in cats by providing immunity against conditions such as feline leukemia virus (FeLV), feline panleukopenia, herpesvirus, and calicivirus, thereby enhancing lifespan and overall feline health. For instance, in June 2025, according to the American Pet Products Association (APPA), a US-based trade association, cat ownership increased by 23 percent in 2024, with households rising from 40 million in 2023 to 49 million in 2024. Consequently, the growing pet cat population is supporting the expansion of the feline vaccines market.
Major companies in the feline vaccines market are focusing on developing advanced products, such as recombinant vector vaccines, to improve efficacy, enhance safety, and offer broader protection. Recombinant vector vaccines are sophisticated immunizations that utilize a harmless virus to deliver specific antigens, eliciting a strong and targeted immune response against the intended pathogen. For instance, in September 2024, MSD Animal Health, a US-based global animal health company, received USDA approval for Nobivac NXT FeLV, a feline leukemia virus vaccine based on its RNA-particle technology platform. This next-generation, non-adjuvanted recombinant canarypox vector vaccine for FeLV is designed to induce robust cell-mediated and humoral immunity, providing enhanced protection against FeLV infection and related diseases. It features a low-volume, subcutaneous dose and is indicated for healthy cats aged 8 weeks or older, aiming to improve safety, ease of administration, and compliance in veterinary practices.
In September 2024, Boehringer Ingelheim International GmbH, a Germany-based biopharmaceutical company, acquired Saiba Animal Health AG for an undisclosed amount. Through this acquisition, Boehringer Ingelheim aims to incorporate Saiba’s virus-like-particle vaccine technology to strengthen its companion animal health portfolio, focusing on chronic diseases in cats and dogs. Saiba Animal Health AG is a Switzerland-based company specializing in the development of virus-like-particle (VLP) vaccines and therapeutics for cats and other companion animals.
Major companies operating in the feline vaccines market are Merck & Co. Inc., Boehringer Ingelheim Animal Health GmbH, Zoetis Inc., Intas Pharmaceuticals Ltd., Elanco Animal Health Incorporated, Ceva Santé Animale S.A., Virbac SA, Neogen Corporation, Laboratorios HIPRA S.A., Vetoquinol SA, Indian Immunologicals Limited, Jinyu Bio-Technology Co. Ltd., Ourofino Animal Health S.A., Biogénesis Bagó S.A., Biovet Private Limited, Hester Biosciences Limited, Biovet S.A., Durvet Inc., China Animal Husbandry Group Co. Ltd., Biopharma Laboratory, Kyoto Biken Laboratories Inc., Nisseiken Co. Ltd., Liaoning Yikang Biological Co. Ltd., Torigen Pharmaceuticals Inc., Bioveta a.s.
North America was the largest region in the feline vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the feline vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the feline vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Tariffs have impacted the feline vaccines market by increasing costs of imported biological raw materials, active pharmaceutical ingredients, and cold chain logistics equipment. The effects are most visible in regions dependent on international vaccine supply chains, including parts of North America and Europe. To mitigate risks, manufacturers are strengthening local production and distribution capabilities. In some cases, tariffs have encouraged domestic vaccine development and improved regional supply security.
Feline vaccines are biological formulations intended to activate a cat’s immune system to identify and protect against specific infectious diseases. They function by presenting harmless antigens or weakened pathogens, allowing the body to develop immunity without causing illness. These vaccines are essential for preventing serious health conditions and limiting the transmission of contagious diseases within feline populations.
The primary types of feline vaccines include inactivated (killed) vaccines, live attenuated vaccines, and recombinant vaccines. Inactivated (killed) vaccines consist of virus particles that have been made non-infectious while still triggering an immune response, providing safety and stability for protecting cats against multiple viral diseases. These vaccines target diseases such as feline panleukopenia virus (FPV), feline calicivirus (FCV), feline herpesvirus type 1 (FHV-1), feline leukemia virus (FeLV), rabies, and feline immunodeficiency virus (FIV). They utilize various technologies, including live attenuated, inactivated, recombinant DNA, subunit, and toxoid-based approaches. Administration routes include injectable, intranasal, and oral vaccines, and they are commonly used by veterinary hospitals, veterinary clinics, and animal research institutes.
The feline vaccines market consists of sales of feline viral rhinotracheitis vaccines, feline calicivirus vaccines, feline panleukopenia vaccines, feline leukemia virus vaccines, and combination multivalent feline vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The feline vaccines market size is expected to see strong growth in the next few years. It will grow to $2.53 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to increasing demand for advanced feline immunization, growing focus on preventive veterinary healthcare, rising adoption of combination vaccines, expanding investment in companion animal biotechnology, and increasing emphasis on early-life vaccination. Major trends in the forecast period include technology-driven vaccine innovations, advancements in recombinant and dna vaccine platforms, developments in adjuvant and antigen delivery systems, rising research and development in feline immunology, and innovation in needle-free and intranasal vaccination methods.
The rising pet cat population is expected to drive the growth of the feline vaccines market in the coming years. Pet cat population refers to the increasing number of domesticated cats kept by households for companionship, emotional support, and recreational purposes. This growth is driven by higher pet adoption rates and the growing recognition of the mental and emotional benefits of pet ownership. Feline vaccines help lower the prevalence of infectious diseases in cats by providing immunity against conditions such as feline leukemia virus (FeLV), feline panleukopenia, herpesvirus, and calicivirus, thereby enhancing lifespan and overall feline health. For instance, in June 2025, according to the American Pet Products Association (APPA), a US-based trade association, cat ownership increased by 23 percent in 2024, with households rising from 40 million in 2023 to 49 million in 2024. Consequently, the growing pet cat population is supporting the expansion of the feline vaccines market.
Major companies in the feline vaccines market are focusing on developing advanced products, such as recombinant vector vaccines, to improve efficacy, enhance safety, and offer broader protection. Recombinant vector vaccines are sophisticated immunizations that utilize a harmless virus to deliver specific antigens, eliciting a strong and targeted immune response against the intended pathogen. For instance, in September 2024, MSD Animal Health, a US-based global animal health company, received USDA approval for Nobivac NXT FeLV, a feline leukemia virus vaccine based on its RNA-particle technology platform. This next-generation, non-adjuvanted recombinant canarypox vector vaccine for FeLV is designed to induce robust cell-mediated and humoral immunity, providing enhanced protection against FeLV infection and related diseases. It features a low-volume, subcutaneous dose and is indicated for healthy cats aged 8 weeks or older, aiming to improve safety, ease of administration, and compliance in veterinary practices.
In September 2024, Boehringer Ingelheim International GmbH, a Germany-based biopharmaceutical company, acquired Saiba Animal Health AG for an undisclosed amount. Through this acquisition, Boehringer Ingelheim aims to incorporate Saiba’s virus-like-particle vaccine technology to strengthen its companion animal health portfolio, focusing on chronic diseases in cats and dogs. Saiba Animal Health AG is a Switzerland-based company specializing in the development of virus-like-particle (VLP) vaccines and therapeutics for cats and other companion animals.
Major companies operating in the feline vaccines market are Merck & Co. Inc., Boehringer Ingelheim Animal Health GmbH, Zoetis Inc., Intas Pharmaceuticals Ltd., Elanco Animal Health Incorporated, Ceva Santé Animale S.A., Virbac SA, Neogen Corporation, Laboratorios HIPRA S.A., Vetoquinol SA, Indian Immunologicals Limited, Jinyu Bio-Technology Co. Ltd., Ourofino Animal Health S.A., Biogénesis Bagó S.A., Biovet Private Limited, Hester Biosciences Limited, Biovet S.A., Durvet Inc., China Animal Husbandry Group Co. Ltd., Biopharma Laboratory, Kyoto Biken Laboratories Inc., Nisseiken Co. Ltd., Liaoning Yikang Biological Co. Ltd., Torigen Pharmaceuticals Inc., Bioveta a.s.
North America was the largest region in the feline vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the feline vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the feline vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Tariffs have impacted the feline vaccines market by increasing costs of imported biological raw materials, active pharmaceutical ingredients, and cold chain logistics equipment. The effects are most visible in regions dependent on international vaccine supply chains, including parts of North America and Europe. To mitigate risks, manufacturers are strengthening local production and distribution capabilities. In some cases, tariffs have encouraged domestic vaccine development and improved regional supply security.
Feline vaccines are biological formulations intended to activate a cat’s immune system to identify and protect against specific infectious diseases. They function by presenting harmless antigens or weakened pathogens, allowing the body to develop immunity without causing illness. These vaccines are essential for preventing serious health conditions and limiting the transmission of contagious diseases within feline populations.
The primary types of feline vaccines include inactivated (killed) vaccines, live attenuated vaccines, and recombinant vaccines. Inactivated (killed) vaccines consist of virus particles that have been made non-infectious while still triggering an immune response, providing safety and stability for protecting cats against multiple viral diseases. These vaccines target diseases such as feline panleukopenia virus (FPV), feline calicivirus (FCV), feline herpesvirus type 1 (FHV-1), feline leukemia virus (FeLV), rabies, and feline immunodeficiency virus (FIV). They utilize various technologies, including live attenuated, inactivated, recombinant DNA, subunit, and toxoid-based approaches. Administration routes include injectable, intranasal, and oral vaccines, and they are commonly used by veterinary hospitals, veterinary clinics, and animal research institutes.
The feline vaccines market consists of sales of feline viral rhinotracheitis vaccines, feline calicivirus vaccines, feline panleukopenia vaccines, feline leukemia virus vaccines, and combination multivalent feline vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Feline Vaccines Market Characteristics
3. Feline Vaccines Market Supply Chain Analysis
4. Global Feline Vaccines Market Trends and Strategies
5. Feline Vaccines Market Analysis of End Use Industries
7. Global Feline Vaccines Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Feline Vaccines Total Addressable Market (TAM) Analysis for the Market
9. Feline Vaccines Market Segmentation
10. Feline Vaccines Market Regional and Country Analysis
11. Asia-Pacific Feline Vaccines Market
12. China Feline Vaccines Market
13. India Feline Vaccines Market
14. Japan Feline Vaccines Market
15. Australia Feline Vaccines Market
16. Indonesia Feline Vaccines Market
17. South Korea Feline Vaccines Market
18. Taiwan Feline Vaccines Market
19. South East Asia Feline Vaccines Market
20. Western Europe Feline Vaccines Market
21. UK Feline Vaccines Market
22. Germany Feline Vaccines Market
23. France Feline Vaccines Market
24. Italy Feline Vaccines Market
25. Spain Feline Vaccines Market
26. Eastern Europe Feline Vaccines Market
27. Russia Feline Vaccines Market
28. North America Feline Vaccines Market
29. USA Feline Vaccines Market
30. Canada Feline Vaccines Market
31. South America Feline Vaccines Market
32. Brazil Feline Vaccines Market
33. Middle East Feline Vaccines Market
34. Africa Feline Vaccines Market
36. Feline Vaccines Market Competitive Landscape and Company Profiles
37. Feline Vaccines Market Other Major and Innovative Companies
40. Feline Vaccines Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Feline Vaccines Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses feline vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for feline vaccines? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The feline vaccines market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Vaccine Type: Inactivated (Killed) Vaccines; Live Attenuated Vaccines; Recombinant Vaccines2) By Disease Type: Feline Panleukopenia Virus (FPV); Feline Calicivirus (FCV); Feline Herpesvirus Type 1 (FHV-1); Feline Leukemia Virus (FeLV); Rabies; Feline Immunodeficiency Virus (FIV); Other disease types
3) By Technology: Live Attenuated; Inactivated; Recombinant deoxyribonucleic acid (DNA); Subunit; Toxoi
4) By Route of Administration: Injectable Vaccines; Intranasal Vaccines; Oral Vaccines
5) By End-User: Veterinary Hospitals; Veterinary Clinics; Animal Research Institutes
Subsegments:
1) By Inactivated (Killed) Vaccines: Whole Virus Vaccines; Split Virus Vaccines; Purified Antigen Vaccines2) By Live Attenuated Vaccines: Modified Live Virus Vaccines; Temperature Sensitive Mutant Vaccines; Attenuated Viral Vector Vaccines
3) By Recombinant Vaccines: Recombinant Viral Vector Vaccines; Recombinant Subunit Vaccines; Deoxyribonucleic Acid (DNA) Based Recombinant Vaccines
Companies Mentioned: Merck & Co. Inc.; Boehringer Ingelheim Animal Health GmbH; Zoetis Inc.; Intas Pharmaceuticals Ltd.; Elanco Animal Health Incorporated; Ceva Santé Animale S.A.; Virbac SA; Neogen Corporation; Laboratorios HIPRA S.A.; Vetoquinol SA; Indian Immunologicals Limited; Jinyu Bio-Technology Co. Ltd.; Ourofino Animal Health S.A.; Biogénesis Bagó S.A.; Biovet Private Limited; Hester Biosciences Limited; Biovet S.A.; Durvet Inc.; China Animal Husbandry Group Co. Ltd.; Biopharma Laboratory; Kyoto Biken Laboratories Inc.; Nisseiken Co. Ltd.; Liaoning Yikang Biological Co. Ltd.; Torigen Pharmaceuticals Inc.; Bioveta a.s.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Feline Vaccines market report include:- Merck & Co. Inc.
- Boehringer Ingelheim Animal Health GmbH
- Zoetis Inc.
- Intas Pharmaceuticals Ltd.
- Elanco Animal Health Incorporated
- Ceva Santé Animale S.A.
- Virbac SA
- Neogen Corporation
- Laboratorios HIPRA S.A.
- Vetoquinol SA
- Indian Immunologicals Limited
- Jinyu Bio-Technology Co. Ltd.
- Ourofino Animal Health S.A.
- Biogénesis Bagó S.A.
- Biovet Private Limited
- Hester Biosciences Limited
- Biovet S.A.
- Durvet Inc.
- China Animal Husbandry Group Co. Ltd.
- Biopharma Laboratory
- Kyoto Biken Laboratories Inc.
- Nisseiken Co. Ltd.
- Liaoning Yikang Biological Co. Ltd.
- Torigen Pharmaceuticals Inc.
- Bioveta a.s.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.91 Billion |
| Forecasted Market Value ( USD | $ 2.53 Billion |
| Compound Annual Growth Rate | 7.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 26 |
